Id: | acc4881 |
Group: | 1sens |
Protein: | eNOS |
Gene Symbol: | NOS3 |
Protein Id: | P29474 |
Protein Name: | NOS3_HUMAN |
PTM: | phosphorylation |
Site: | Ser1177 |
Site Sequence: | EVTSRIRTQSFSLQERQLRGA |
Disease Category: | Endocrine and metabolic diseases |
Disease: | High Glucose |
Disease Subtype: | |
Disease Cellline: | HUVECs |
Disease Info: | |
Drug: | TEPP-46 |
Drug Info: | TEPP-46 is a chemical compound that may be used in pharmacological research or as a drug candidate. |
Effect: | modulate |
Effect Info: | TEPP - 46 → Inhibit PKM2 phosphorylation → Inhibit eNOS phosphorylation. The conclusion is that p - PKM2 may be involved in the process of endothelial - dependent vasodilation dysfunction in type 2 diabetes by inhibiting the p - eNOS(Ser1177)/NO pathway. |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 37539568 |
Sentence Index: | 37539568_16 |
Sentence: | High glucose instead of mannitol induced the increase of PKM2 phosphorylation in HUVECs and reduced the level of NO in supernatant (both P<0.05). |
Sequence & Structure:
MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDDPPELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
NOS3 | TILARGININE ACETATE | Nitric oxide synthase inhibitor | 3 | Terminated | Shock | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 3 | Terminated | Shock | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 2 | Terminated | anemia (phenotype) | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 2 | Completed | sickle cell anemia | ClinicalTrials ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 2 | Completed | hyperlipidemia | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Terminated | HIV infection | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Withdrawn | hypoxia | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | serum lipopolysaccharide activity | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | sarcopenia | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | breast cancer | ClinicalTrials |
NOS3 | TILARGININE | Nitric oxide synthase inhibitor | 1 | Completed | sickle cell anemia | ClinicalTrials ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNOS3-Ser1177 | |
---|---|
Cancer | Intensity |
BRCA | 0.71 |
COAD | 0.399 |
HGSC | 1.182 |
ccRCC | 0.059 |
GBM | -0.83 |
HNSC | 0.225 |
LUAD | 0.965 |
LUSC | 0.783 |
non_ccRCC | -1.984 |
PDAC | -0.216 |
UCEC | -1.292 |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.